GlassScriptPhysician profile
Samina T Syed
NPI 1851565212
$1,010.22
in general payments reported to CMS, 2019-2025
18 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.32 · 2020: $32.84 · 2021: $86.11 · 2022: $83.88 · 2023: $159 · 2024: $219 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $174.76 | 2021-2025 | |
| Abbott Laboratories | $174.45 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $166.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $89.93 | 2019-2025 | Tepezza |
| Recordati_rare_diseases_inc. | $60.79 | 2023-2025 | Isturisa, Signifor Lar |
| Insulet Corporation | $53.21 | 2024 | Omnipod |
| Medtronic, INC. | $43.08 | 2022-2023 | Minimed 780g |
| Amphastar Pharmaceuticals, INC. | $37.51 | 2023-2024 | Baqsimi |
| Neurocrine Biosciences, INC. | $34.85 | 2024 | |
| Pfizer INC. | $34.61 | 2021-2023 | |
| Horizon Therapeutics Plc | $27.60 | 2023 | Tepezza |
| Sequel Med Tech, LLC | $19.91 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $18.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.48 | 2020 | |
| Amneal Pharmaceuticals LLC | $16.36 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $14.97 | 2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $14.50 | 2019 | |
| Amarin Pharma, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samina Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.